SEC Filings

Form 424B3
ZOMEDICA PHARMACEUTICALS CORP. filed this Form 424B3 on 11/13/2018
Document Outline
Entire Document (603.4 KB)
Subdocument 1 - 424B3 - 424B3
Page 1 - Filed pursuant to Rule 424(b)(3)
Page 2 - UNITED STATES
Page 3 - Zomedica Pharmaceuticals Corporation
Page 4 - PART I FINANCIAL INFORMATION
Page 5 - Zomedica Pharmaceuticals Corp.
Page 6 - Zomedica Pharmaceuticals Corp.
Page 7 - Zomedica Pharmaceuticals Corp.
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - Issued and outstanding common stock:
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - Item 2. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Page 22 - MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
Page 23 - Revenue
Page 24 - General and Administrative Expense
Page 25 - Use of Estimates
Page 26 - Loss Per Share
Page 27 - General and administrative expense for the three months ended September 30, 2018 was $834,570 compar
Page 28 - Cash Flows
Page 29 - Financing Activities
Page 30 - N/A
Page 31 - Off Balance Sheet Arrangements
Page 32 - PART II OTHER INFORMATION
Page 33 - N/A
Page 34 - We are substantially dependent on the success of our lead product candidates, and cannot be certain
Page 35 - Development of product candidates for use in companion animal health is an inherently expensive, tim
Page 36 - We will rely on third parties to conduct certain portions of our development activities. If these th
Page 37 - Risks Related to Intellectual Property
Page 38 - SIGNATURES
Page 39 - EXHIBIT INDEX